Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Other Operating Expenses (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Other Operating Expenses for 14 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses fell 13.9% to $2.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.0 million through Dec 2025, up 19.25% year-over-year, with the annual reading at $13.0 million for FY2025, N/A changed from the prior year.
  • Other Operating Expenses hit $2.5 million in Q4 2025 for Corcept Therapeutics, down from $4.6 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $4.6 million in Q3 2025 to a low of $1.2 million in Q1 2022.
  • Historically, Other Operating Expenses has averaged $2.1 million across 5 years, with a median of $1.6 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: crashed 32.48% in 2021 and later soared 82.9% in 2024.
  • Year by year, Other Operating Expenses stood at $1.4 million in 2021, then grew by 9.31% to $1.5 million in 2022, then rose by 26.82% to $1.9 million in 2023, then skyrocketed by 57.49% to $3.0 million in 2024, then decreased by 13.9% to $2.5 million in 2025.
  • Business Quant data shows Other Operating Expenses for CORT at $2.5 million in Q4 2025, $4.6 million in Q3 2025, and $3.4 million in Q2 2025.